Kyle Bass

Will Kyle Bass's Win Lead To More Hedge Fund Patent Challenges?

As the sting of hedge fund manager Martin Shkreli’s Turing Pharmaceuticals raising the price of an important drug from $13.50 per tablet to $750, comes a victory for hedge fund manager Kyle Bass, who is challenging pharmaceutical patents and says his actions will lower drug prices.
U.S. Patent and Trademarket Office rules with Kyle Bass
In a victory for Bass, a tribunal at the U.S. Patent and Trademark Office was exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible


Saved Articles
X
TextTExtLInkTextTExtLInk

Are you a smart investor? Join tens of thousands of sophisticated investor reading our authoritative free newsletter

* indicates required


Congrats! Are you a smart person?

We have an exclusive targeted for being a sophisticated and loyal reader.

Sign up for ValueWalkPremium today and get our exclusive content for 35% off.

Use coupon code vip19 or click on the button below

Limited time offer only ENDS 11/30/2019 or after next 25 13 subscribers take advantage whichever comes first – please do not share this discount with others

 

0